ABSTRACT
OBJECTIVE To exc avate the adverse drug event （ADE）signals of semaglutide and provide reference for its clinical rational use. METHODS The proportional unbalance method was used to mine the signals of all semaglutide ADE reports from FDA Adverse Event Reporting System （FAERS）up to September 2021. The basic situations of the reported cases were analyzed. The corresponding system organ classification （SOC）was mapped and compared with the adverse drug reactions recorded in the drug instructions. Preferred terms （PT）of patients with different indications were analyzed. RESULTS A total of 6 661 semaglutide ADE reports were extracted and 194 valid signals were mined. Among 6 661 cases of ADE ，the proportion of men （43.40％）was lower than women （52.65％）；the age was mainly distributed in ＞40-65 years old （29.00％）and ＞65 years old （22.61％）；the reporting country was mainly the United States （83.88％）；the report year was mainly concentrated in 2021 （40.88％），with an increasing trend year by year ；the main outcome was hospitalization or prolonged hospitalization in serious ADE reports （17.78％）. Semaglutide ADE signal was mapped to the main SOC ，mainly including gastrointestinal diseases ，various injuries，poisoning and operation complications ，metabolic and nutritional diseases ，various examinations. The screening criteria were based on the report odds ratio ＞10 or ADE reported cases ＞50，and 48 new potential adverse drug reactions were added to the drug description. Among the indications with the top two reported cases （type 2 diabetes and obesity ，overweight，weight control），the frequency of gastrointestinal system related ADE reports represented by nausea ，vomiting and diarrhea was higher ， which was similar to the drug instructions. CONCLUSIONS This study supplemented 48 new potential adverse drug reactions based on the drug instructions of semaglutide. At present ，it can be considered that semaglutide is safe.
ABSTRACT
OBJECTIVE To explore and establis h a general pharmacist system suitable for China ’s national conditions ，and to improve the rational use of drugs in primary medical institutions . METHODS Under the leadership of Tianhe District Health Bureau of Guangzhou ，relying on the regional pharmaceutical specialty alliance ，general pharmacist system of medical consortium was established ，and the general pharmacist was responsible for the overall planning of pharmaceutical care in the medical consortium. The joint management office of pharmaceutical care was established ，and the training of the pharmacists in the medical consortium was organized. A regional audit center was established to realize the prescription review of 13 community health service centers in the medical consortium. “Internet plus ”home pharmaceutical care was carried out ，and science popularization education was provided for communities ，schools，enterprises and institutions. RESULTS After systematic training and assessment ，three pharmacist teams had been successfully established in the medical consortium to provide prescription review ，science popularization and education and family pharmacist services for community residents ；the regional audit center successfully intercepted 17.17％ of unreasonable prescriptions ，reducing the amount of unreasonable drug use by a total of 6.56 million yuan. After the intervention of prescription review system ，the qualified rate of outpatient prescriptions in community health service centers was ≥95％，and the qualified rate increased by an average of 6％. The department of pharmaceutical science popularization and education held 35 science popularization and free clinic activities ，of which 71.20％ of the residents believed that the activities had improved their understanding of drugs. In addition ，111 cases patients serviced by home pharmaceutical care were carried out successfully by pharmacist team ，and the patients ’acceptance of pharmacist intervention was 91.89％ . CONCLUSIONS Under the new medical reform ，it is feasible to implement a regional general pharmacist system within the medical consortium ， which improves the pharmaceutical administration and pharmaceuticalcare capabilities of m edical institutions in the medical consortium，as well as the level of rational drug use ，and reduces the me dical burden.
ABSTRACT
Objective@#To explore the clinical effect of Ginkgo biloba capsule combined with isosorbide mononitrate in the treatment of angina pectoris of coronary heart disease.@*Methods@#From April 22, 2017 to April 22, 2018, 100 patients with coronary heart disease and angina pectoris admitted to Zhoushan Traditional Chinese Medicine Hospital were enrolled in the study.Fifty patients in the control group were treated with isosorbide mononitrate.Fifty patients in the observation group were treated with Ginkgo biloba capsules and isosorbide mononitrate.The left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), duration of angina pectoris, frequency of angina attacks, total effective rate, incidence of adverse reactions, angina relief time were observed.@*Results@#The LVEDD, LVESD, LVEF, total effective rate, incidence rate of adverse reaction, duration of angina pectoris, angina pectoris frequency and angina pectoris remission time in the observation group were (48.41±2.23)mm, (30.89±1.12)mm, (56.55±5.87)%, 96.00%, 4.00%, (3.44±1.52)min/time, (1.36±0.54)times/week, (3.12±0.56)min, respectively, which were better than those in the control group [LVEDD (64.78±2.89)mm, LVESD (42.21±1.55)mm, LVEF (43.46±1.52)%, total effective rate (74.00%), incidence rate of adverse reactions (28.00%), duration of angina pectoris (5.68±1.66)min/time, frequency of angina pectoris (2.68±1.47)times/week, angina relief time (4.87±1.41)min] (t=19.546, 41.857, 15.264, χ2=9.490, 10.714, t=7.037, 5.960, 8.156, all P<0.05).@*Conclusion@#Ginkgo biloba capsule combined with isosorbide mononitrate is effective in the treatment of patients with coronary heart disease and angina pectoris.
ABSTRACT
Objective To explore the clinical effect of Ginkgo biloba capsule combined with isosorbide mononitrate in the treatment of angina pectoris of coronary heart disease .Methods From April 22,2017 to April 22, 2018,100 patients with coronary heart disease and angina pectoris admitted to Zhoushan Traditional Chinese Medicine Hospital were enrolled in the study.Fifty patients in the control group were treated with isosorbide mononitrate.Fifty patients in the observation group were treated with Ginkgo biloba capsules and isosorbide mononitrate .The left ventricular end －diastolic diameter ( LVEDD), left ventricular end －systolic diameter ( LVESD), left ventricular ejection fraction (LVEF),duration of angina pectoris ,frequency of angina attacks ,total effective rate,incidence of adverse reactions, angina relief time were observed.Results The LVEDD, LVESD, LVEF, total effective rate, incidence rate of adverse reaction,duration of angina pectoris ,angina pectoris frequency and angina pectoris remission time in the observation group were (48.41 ±2.23)mm,(30.89 ±1.12)mm,(56.55 ±5.87)%,96.00%,4.00%, (3.44 ±1.52)min／time,(1.36 ±0.54)times／week,(3.12 ±0.56) min,respectively,which were better than those in the control group [LVEDD (64.78 ±2.89) mm,LVESD (42.21 ±1.55) mm,LVEF (43.46 ±1.52)%,total effective rate (74.00%), incidence rate of adverse reactions ( 28.00%), duration of angina pectoris (5.68 ± 1.66)min／time,frequency of angina pectoris (2.68 ±1.47)times／week,angina relief time (4.87 ±1.41)min] (t＝19.546,41.857,15.264,χ2 ＝9.490,10.714,t＝7.037,5.960,8.156,all P＜0.05).Conclusion Ginkgo biloba capsule combined with isosorbide mononitrate is effective in the treatment of patients with coronary heart disease and angina pectoris.